Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib versus docetaxel in previously treated mutation-positive advanced non-small cell lung cancer
NL-OMON38298Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Trametinib with Docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Nov 2011; status: active, not recruiting.
02
Drugs
trametinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON38298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38298.